Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)
Status:
Withdrawn
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study is needed to assess the feasibility of integrating this therapy with current
treatment regimens. If this study shows success a formal phase II test study to conduct
feasibility will be the next step. The first dose level chosen for this study is 66Gy of
radiation to the tumor between LET and standard photon therapy. This dose is the current
standard of care for stage III . If this dose is found to be feasible then the dose of LET
will escalate to the total dose of 74Gy.